Clincosm LogoSign in Get a demo

non hodgkin lymphoma

Showing 51 - 75 of 127
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin Lymphoma Trial in Worldwide (Epcoritamab)

Recruiting
  • Non Hodgkin Lymphoma
  • Palo Alto, California
  • +44 more
Aug 12, 2022

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (KRT-232, acalabrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Goshen, Indiana
  • +44 more
Aug 3, 2022

Hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in United States (AB-205, Placebo)

Recruiting
  • Hodgkin Lymphoma
  • Non Hodgkin Lymphoma
  • AB-205
  • Placebo
  • Duarte, California
  • +20 more
Aug 2, 2022

Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib, Rituximab, Bendamustine)

Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Tucson, Arizona
  • +134 more
Jul 27, 2022

Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia Trial in Houston (iCaspase9-transduced T cells,

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • +9 more
  • iCaspase9-transduced T cells
  • AP1903
  • Houston, Texas
  • +1 more
Jul 22, 2022

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in United States (TGR-1202, TGR-1202 + Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +16 more
Jul 20, 2022

Improving Communication and BuildingStronger Medical Home Among

Recruiting
  • Leukemia
  • Non Hodgkin Lymphoma
  • Interview
  • Aurora, Colorado
    Children's Hospital Colorado
Jun 15, 2022

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Jinan (CAR-T cells)

Recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +2 more
  • CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jun 14, 2022

Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Beijing (CAR-NK-CD19 Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • +2 more
  • CAR-NK-CD19 Cells
  • Beijing, Beijing, China
    Beijing Boren Hospital
Jun 5, 2022

Familial Investigations of Childhood Cancer Predisposition

Recruiting
  • Acute Leukemia
  • +45 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    May 11, 2022

    Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +8 more
    • Miami, Florida
    • +2 more
    Apr 21, 2022

    Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia Trial in United States (BTX-1188)

    Recruiting
    • Advanced Solid Tumor
    • +2 more
    • Duarte, California
    • +3 more
    Apr 18, 2022

    Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • +2 more
    • Guandong, Guangdong, China
    • +2 more
    Apr 6, 2022

    Hodgkin Lymphoma, Non Hodgkin Lymphoma, Leukemia Trial in Palo Alto (Biostrap arm band)

    Recruiting
    • Hodgkin Lymphoma
    • +3 more
    • Biostrap arm band
    • Palo Alto, California
      Stanford University
    Mar 29, 2022

    Non Hodgkin Lymphoma Trial (Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • Liposomal Mitoxantrone Hydrochloride dose level 1
    • +6 more
    • (no location specified)
    Mar 17, 2022

    Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)

    Withdrawn
    • Acute Lymphoblastic Leukemia
    • +2 more
    • PACE CART19
    • (no location specified)
    Mar 9, 2022

    Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +4 more
    • DA-EPOCH-R followed by Nivolumab
    • Antwerpen, Belgium
    • +23 more
    Mar 23, 2022

    Lymphoma Patients Undergoing Mediastinal Radiotherapy in Era of

    Suspended
    • Mediastinal Lymphoma
    • +2 more
    • Standard treatment protocol with combined chemoradiation
    • Taoyuan, Taiwan
      Chang Gung Memorial Hospital
    Mar 8, 2022

    Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma Trial in Lyon (PASCA intervention)

    Recruiting
    • Late Effects
    • +8 more
    • PASCA intervention
    • Lyon, France
      Centre Leon Berard
    Mar 15, 2022

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)

    Recruiting
    • Non Hodgkin Lymphoma
    • Diffuse Large B Cell Lymphoma
    • Nanjing, Jiangsu, China
    • +1 more
    Mar 9, 2022

    Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib (ME-401))

    Recruiting
    • Follicular Lymphoma (FL)
    • +2 more
    • Zandelisib (ME-401)
    • Tucson, Arizona
    • +115 more
    Mar 8, 2022

    Lung Tumors, NSCLC, Carcinoma, Small Cell Trial in Worldwide (CK-301 (cosibelimab))

    Recruiting
    • Lung Neoplasms
    • +12 more
    • CK-301 (cosibelimab)
    • Wollongong, New South Wales, Australia
    • +47 more
    Mar 3, 2022

    Hodgkin Lymphoma, Lymphoid Leukemia, Multiple Myeloma Trial in Richmond (Intravenous (IV) and oral Vitamin C)

    Active, not recruiting
    • Hodgkin Lymphoma
    • +6 more
    • Intravenous (IV) and oral Vitamin C
    • Richmond, Virginia
      Virginia Commonwealth University/ Massey Cancer Center
    Mar 2, 2022

    Non Hodgkin Lymphoma Trial in Cologne, Essen (CTL019)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • Cologne, Germany
    • +1 more
    Mar 2, 2022

    Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in China (APG-2575)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Non Hodgkin Lymphoma
    • Hefei, Anhui, China
    • +4 more
    Feb 23, 2022